Figure 2From: Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trialsForest plot for the comparison of median survival. FDR gemcitabine provided longer median survival than standard gemcitabine (Mean Difference = 1.24 months, 95% CI: 0.39-2.09). FDR: fixed-dose rate; SD: standard deviation; CI: confidence intervals.Back to article page